Pharmacogenomics of anthracycline-cyclophosphamide-taxane chemotherapy: an influence of <i>CYP</i> polymorphisms and BMI on breast cancer treatment outcomes
AA genotype at G681A in low BMI patients showed the poorest chemotherapy response and lowest PFS (HR>1). <i>CYP2C19</i> variants (AA) may serve as predictive markers for non-responsiveness towards AC-T chemotherapy in low BMI BC patients, highlighting the need for genetic counselling and nutritional support to improve treatment outcomes.
Authors
- Neyaz Alam (ORCID: https://orcid.org/0000-0002-2941-6769)
- Tanuma Mistry (ORCID: https://orcid.org/0000-0001-5501-9903)
- Vilas D. Nasare (ORCID: https://orcid.org/0000-0002-0016-9610)
- Partha Nath
Institutions
- Jadavpur University (IN)
- Chittaranjan National Cancer Institute (IN)
Publication Details
- Journal
- Pharmacogenomics
- Published
- 2025-11-02
- DOI
- https://doi.org/10.1080/14622416.2025.2593225
- Primary Topic
- Cancer Risks and Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00